Lys305

Site Information
GIEIPAEkVFLAQkM SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 474712

In vivo Characterization
Methods used to characterize site in vivo:	immunoassay ( 1 , 6 ) , immunoprecipitation ( 1 , 6 ) , mass spectrometry ( 1 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ) , modification-specific antibody ( 1 , 6 ) , mutation of modification site ( 1 , 6 ) , western blotting ( 1 , 6 )
Disease tissue studied:	breast cancer ( 1 ) , liver cancer ( 35 ) , hepatocellular carcinoma ( 35 ) , lung cancer ( 1 , 6 ) , non-small cell lung cancer ( 1 , 6 ) , prostate cancer ( 6 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , E.coli (bacterial) ( 6 ) , HCT116 (intestinal) ( 21 , 22 , 23 ) , HCT15 (intestinal) ( 31 , 32 ) , HCT8/S11 (intestinal) ( 33 , 34 ) , HEK293T (epithelial) ( 1 , 6 ) , HeLa (cervical) ( 1 , 3 ) , HepG2 (hepatic) ( 35 ) , HT-29 (intestinal) ( 25 , 26 ) , Jurkat (T lymphocyte) ( 4 , 8 , 17 ) , KMS-18 (B lymphocyte) ( 10 ) , liver ( 7 ) , LNCaP (prostate cell) ( 6 ) , MCF-7 (breast cell) ( 1 ) , MMTV-PyMT (breast cell) ( 1 ) , NCI-H1299 (pulmonary) ( 1 , 6 ) , NCI-H1650 (pulmonary) ( 16 ) , NCI-H716 (intestinal) ( 29 , 30 ) , OCI-ly3 (B lymphocyte) ( 12 , 14 ) , RC-K8 (B lymphocyte) ( 13 , 15 ) , SEM (B lymphocyte) ( 11 ) , SNU-C2B (intestinal) ( 24 ) , SW48 (intestinal) ( 27 , 28 ) , SW480 (intestinal) ( 18 ) , SW620 (intestinal) ( 19 , 20 )

Upstream Regulation
Treatments:	glucose ( 6 ) , low_glucose ( 1 ) , nicotinamide ( 6 ) , serum_starvation ( 1 ) , siRNA ( 1 , 6 ) , trichostatin_A ( 1 , 6 )

Downstream Regulation
Effects of modification on PKM:	enzymatic activity, induced ( 1 ) , enzymatic activity, inhibited ( 6 ) , intracellular localization ( 6 ) , molecular association, regulation ( 6 ) , protein degradation ( 6 )
Effects of modification on biological processes:	autophagy, induced ( 6 ) , carcinogenesis, induced ( 1 , 6 ) , cell growth, induced ( 6 )
Induce interaction with:	HSC70 (human) ( 6 )
Inhibit interaction with:	Other ( 6 )

Disease / Diagnostics Relevance
Relevant diseases:	breast cancer ( 1 ) , prostate cancer ( 6 )

References
1	Park SH, et al. (2016) SIRT2-Mediated Deacetylation and Tetramerization of Pyruvate Kinase Directs Glycolysis and Tumor Growth. Cancer Res 76, 3802-12 27197174 Curated Info
2	Wang P, Sun C, Zhu T, Xu Y (2015) Structural insight into mechanisms for dynamic regulation of PKM2. Protein Cell 6, 275-87 25645022 Curated Info
3	Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51 23954790 Curated Info
4	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
5	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
6	Lv L, et al. (2011) Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42, 719-30 21700219 Curated Info
7	Zhao S, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-4 20167786 Curated Info
8	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
9	Cherry J (2007) CST Curation Set: 2726; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Cherry J (2007) CST Curation Set: 2727; Year: 2007; Biosample/Treatment: cell line, KMS-18/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
11	Cherry J (2007) CST Curation Set: 2712; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
12	Cherry J (2007) CST Curation Set: 2513; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
13	Cherry J (2007) CST Curation Set: 2436; Year: 2007; Biosample/Treatment: cell line, RC-K8/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
14	Cherry J (2007) CST Curation Set: 2437; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
15	Cherry J (2007) CST Curation Set: 2438; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
16	Guo A (2007) CST Curation Set: 2324; Year: 2007; Biosample/Treatment: cell line, NCI-H1650/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
17	Possemato A (2006) CST Curation Set: 2188; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
18	Li Y (2006) CST Curation Set: 1971; Year: 2006; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
19	Li Y (2006) CST Curation Set: 1973; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
20	Li Y (2006) CST Curation Set: 1828; Year: 2006; Biosample1/Treatment/Isotope: cell line, SW620/serum starved &'\|\|' serum starved/L, Biosample2/Treatment/Isotope: cell line, SW620/serum starved/TSA/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
21	Li Y (2006) CST Curation Set: 1810; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCT116/serum starved &'\|\|' EGF/L, Biosample2/Treatment/Isotope: cell line, HCT116/serum starved/serum starved/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
22	Li Y (2006) CST Curation Set: 1658; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
23	Li Y (2006) CST Curation Set: 1659; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
24	Li Y (2006) CST Curation Set: 1641; Year: 2006; Biosample/Treatment: cell line, SNU-C2B/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
25	Li Y (2006) CST Curation Set: 1632; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
26	Li Y (2006) CST Curation Set: 1633; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
27	Li Y (2006) CST Curation Set: 1564; Year: 2006; Biosample/Treatment: cell line, SW48/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
28	Li Y (2006) CST Curation Set: 1565; Year: 2006; Biosample/Treatment: cell line, SW48/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
29	Li Y (2006) CST Curation Set: 1566; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
30	Li Y (2006) CST Curation Set: 1567; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
31	Li Y (2006) CST Curation Set: 1469; Year: 2006; Biosample/Treatment: cell line, HCT15/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
32	Li Y (2006) CST Curation Set: 1472; Year: 2006; Biosample/Treatment: cell line, HCT15/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
33	Li Y (2006) CST Curation Set: 1475; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
34	Li Y (2006) CST Curation Set: 1476; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
35	Mitchell J (2005) CST Curation Set: 869; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info